Serum Urate Goals Tied to Lower CV Risk - Summary - MDSpire
From the Journals

Serum Urate Goals Tied to Lower CV Risk

Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients

  • By

  • Andrea Surnit

  • May 11, 2026

  • 4 min

Share

A study published in JAMA Internal Medicine indicates that patients with gout who achieve serum urate targets outlined in guidelines have a significantly lower five-year risk of major adverse cardiovascular events. Analyzing data from over 109,000 adults, researchers found a weighted hazard ratio of 0.91 for those reaching urate levels below 6 mg/dL, with further benefits for levels below 5 mg/dL. Although findings suggest a link between gout flare reduction and cardiovascular risk, limitations such as residual confounding must be considered.

Original Source(s)

Serum Urate Goals Tied to Lower CV Risk

  • by Andrea Surnit

  • May 11, 2026

Related Content

Tofacitinib vs Adalimumab Findings Require Caution in RA

Meta-analysis favored tofacitinib for some rheumatoid arthritis outcomes, but high heterogeneity, dose-dependent effects, and JAK inhibitor safety concerns complicate interpretation.

Lung Disease Complicates RA Care

Patients with chronic lung disease had numerically lower remission rates and substantially more serious adverse events in a 5-year Japanese registry study of late-onset rheumatoid arthritis.

Deep Remission Tied to RA Control

At 5 years, 63% of patients in the CliDR group maintained sustained remission compared with 38% in the non-CliDR group.